Videos

Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.

Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.

Tony S. Mok, MD, spoke about future research efforts focused on capmatinib plus pembrolizumab in patients with previously untreated MET-unselected, PD-L1–positive non–small cell lung cancer.

Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.

Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.

Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.

Roger Li, MD, spoke about the safety profile of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.

Karen L. Reckamp, MD, spoke about current other Lung-MAP and what her colleague can take away from the phase 2 substudy S1800A presented at 2022 ASCO.

Mark Pegram, MD, spoke about predictive and prognostic factors used to determine which patients with early-stage hormone receptor–positive breast cancer benefit from extended vs standard adjuvant endocrine therapy.

A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.

Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.

Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.

Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Rita Nanda, MD, leads a discussion of the first clinical scenario, a 41-year-old woman with HER2+ metastatic breast cancer who progressed on docetaxel/trastuzumab/pertuzumab.

To begin the program, an expert panel of leaders in the management of HER2+ metastatic breast cancer provides an overview of the disease landscape.

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.

Mark Pegram, MD, spoke about using the Breast Cancer Index and Clinical Treatment Score post-5 years to determine outcomes for patients with early-stage hormone receptor–positive breast cancer treated with adjuvant endocrine therapy.

Amrita Y. Krishnan, MD, spoke about where future research in multiple myeloma is headed and a take-home message for her colleagues about teclistamab in heavily pretreated patients.

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

Roger Li, MD, spoke about responses from the CORE1 trial that examined patients with non–muscle invasive bladder cancer treated with CG0070 plus pembrolizumab.

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Steven J. Chmura, MD, PhD, spoke about interesting findings from a phase 2R/3 trial of patients with newly oligometastatic breast cancer who were given standard of care systemic treatment with or without stereotactic body radiotherapy and/or surgical resection.

Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.